CAJ | 학술논문

目的：分析吉西他滨联合卡培他滨治疗蒽环类耐药的转移性乳腺癌的临床疗效和安全性。方法将2008年6月至2012年6月我院收治的91例对蒽环类耐药的转移性乳腺癌患者为研究对象，并将其随机分为两组，即吉西他滨组45例，给予吉西他滨联合卡培他滨治疗，多西紫杉醇组46例，给予多西紫杉醇联合卡培他滨治疗，21天为1疗程，每疗程进行毒副作用评估，两组均治疗2疗程后对比临床疗效。结果吉西他滨组的总缓解率（44.44％）明显高于多西紫杉醇组（21.74％）（P<0.05）；吉西他滨组Ⅲ、Ⅳ度骨髓抑制发生率（17.78％）和Ⅲ、Ⅳ度消化道毒副作用发生率（20.00％）均明显低于多西紫杉醇组（39.13％,43.48％）（P<0.05）。结论吉西他滨联合卡培他滨治疗蒽环类耐药的转移性乳腺癌疗效较多西紫杉醇联合卡培他滨更好，且不良反应的发生率更低，值得临床推广。
목적：분석길서타빈연합잡배타빈치료은배류내약적전이성유선암적림상료효화안전성。방법장2008년6월지2012년6월아원수치적91례대은배류내약적전이성유선암환자위연구대상，병장기수궤분위량조，즉길서타빈조45례，급여길서타빈연합잡배타빈치료，다서자삼순조46례，급여다서자삼순연합잡배타빈치료，21천위1료정，매료정진행독부작용평고，량조균치료2료정후대비림상료효。결과길서타빈조적총완해솔（44.44％）명현고우다서자삼순조（21.74％）（P<0.05）；길서타빈조Ⅲ、Ⅳ도골수억제발생솔（17.78％）화Ⅲ、Ⅳ도소화도독부작용발생솔（20.00％）균명현저우다서자삼순조（39.13％,43.48％）（P<0.05）。결론길서타빈연합잡배타빈치료은배류내약적전이성유선암료효교다서자삼순연합잡배타빈경호，차불량반응적발생솔경저，치득림상추엄。
Objective To analyze the clinical efficacy and safety of gemcitabine plus capecitabine in the treatment of anthra-cycline-resistant metastatic breast cancer. Methods Ninety-one cases of anthracycline-resistant metastatic breast cancer patients admitted in our hospital between June 2008 and June 2012 were selected and randomly divided into two groups. Forty-five cases in the gemcitabine group were given gemcitabine combined with capecitabine, and 46 cases in the docetaxel group were given docetaxel plus capecitabine treatment. 21 d was taken as a treatment cycle, and the toxic effects were assayed after each cycle. The clinical efficacy were observed and compared between two groups after two treatment cycles. Results The total re-mission rate in the gemcitabine group (44.44%) was significantly higher than that of the paclitaxel group (21.74%) (P<0.05). The incidence rates ofⅢdegree,Ⅳdegree of bone marrow suppression (17.78%) and gastrointestinal side effects (20.00%) were both significantly lower in the gemcitabine group than in the docetaxel group (39.13%and 43.48%respectively) (P<0.05). Conclusion Treatment with gemcitabine plus capecitabine was more effective than the treatment with docetaxel plus capecitab-ine in treating anthracycline-resistant metastatic breast cancer, with lower incidence rates of adverse reactions. It was worthy of being popularized.